Krebs Biochemicals and Industries financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹5.8cr+38.9% on Q2 FY26
Net profit
−₹5.4cr−₹6.1 cr in Q2 FY26
EBITDA margin
−33.3%+33.7 pts on Q2 FY26
EPS
−₹2.50−₹2.85 in Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue5.84.2+38.9%
EBITDA−1.9−2.8—
EBITDA margin−33.3%−67.0%+33.7 pts
Profit before tax−5.4−6.1—
Net profit−5.4−6.1—
EPS−₹2.50−₹2.85—

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹5.8 crNet profit₹−5.4 crNet margin−93.2%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
128————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.10.10.10.10.1
225225212193183
352————
26.923.743.350.452.1
—−45.2%−14.1%−3.3%—
−1.7−5.5−15.0−8.7−15.8
−6.2%−23.0%−34.7%−17.3%−30.3%
−8.1−11.9−21.7−15.5−22.3
−13.3−16.9−26.9−19.7−24.7
−49.7%−71.4%−62.2%−39.1%−47.4%
−₹6.19−₹7.85−₹12.49−₹9.15−₹11.45
—+37.1%−36.6%+20.1%—
—−1.9−7.92.3−26.5
—−4.0−5.1−7.8−10.9
−5.9−5.9−13.0−5.5−37.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KREBSBIO₹59.15

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹128 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————127.5
- Cash, Equiv & ST Investments0.10.10.10.10.1
+ Total Debt183.2193.4212.2224.8224.8
Enterprise Value————352.2
Revenue52.150.443.323.726.9
Growth %, YoY—-3.3-14.1-45.2—
EBITDA-15.8-8.7-15.0-5.5-1.7
Margin %-30.27-17.30-34.70-22.97-6.23
EBIT-22.3-15.5-21.7-11.9-8.1
Net Income-24.7-19.7-26.9-16.9-13.3
Margin %-47.36-39.13-62.20-71.35-49.71
EPS, Adj (current shares)-11.45-9.15-12.49-7.85-6.19
Growth %, YoY—+20.1-36.6+37.1—
Cash from Operations-26.52.3-7.9-1.9—
Capital Expenditures-10.9-7.8-5.1-4.0—
Free Cash Flow-37.4-5.5-13.0-5.9-5.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Krebs Biochemicals and Industries financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Krebs Biochemicals and Industries (NSE: KREBSBIO) had a market capitalisation of ₹125 crore at the 29 October 2026 close (₹57.93 a share). In FY26 its consolidated net loss was ₹16.9 crore on revenue of ₹23.7 crore; in Q2 FY27 (July–September 2026) it was a loss of ₹5.4 crore. Its net worth was negative (−₹171 crore) on 30 September 2026, with borrowings of ₹227 crore. Promoters held 72.74% of the shares on 30 September 2026.

Share price used
₹57.93 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Krebs Biochemicals and Industries at a glance · consolidated

Market cap
₹125 Crat ₹57.93 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Net worth
−₹171 Crnegative equity · 30 September 2026
Promoter holding
72.74%unchanged vs 30 Jun 202630 September 2026
Free cash flow (FY26)
−₹5.9 Cr
EPS (FY26)
−₹7.85

Questions

What is the Krebs Biochemicals and Industries PE ratio today?

Krebs Biochemicals and Industries' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q3 FY26 to Q2 FY27) was a loss of ₹13.3 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹125 crore at ₹57.93 a share.

What is the Krebs Biochemicals and Industries debt to equity ratio?

Krebs Biochemicals and Industries' debt-to-equity ratio is not meaningful: its total equity was negative (−₹171 crore) on 30 September 2026, against borrowings of ₹227 crore. A negative equity means accumulated losses exceed the capital shareholders put in.

What is the Krebs Biochemicals and Industries net worth?

Krebs Biochemicals and Industries' net worth was negative on 30 September 2026: shareholders' equity of −₹171 crore in its consolidated balance sheet, meaning accumulated losses exceed the capital put in. The market still values the company at ₹125 crore (market capitalisation at the 29 October 2026 close).

What is the Krebs Biochemicals and Industries market cap?

Krebs Biochemicals and Industries' market capitalisation was ₹125 crore at the 29 October 2026 close: 2.16 crore shares at ₹57.93 each.

Is Krebs Biochemicals and Industries debt free?

No. Krebs Biochemicals and Industries had borrowings of ₹227 crore on 30 September 2026 (consolidated balance sheet). Its cash and current investments were ₹13 lakh, so its net debt was ₹227 crore.

What is the Krebs Biochemicals and Industries EPS?

Krebs Biochemicals and Industries' basic earnings per share (EPS) were −₹7.85 in FY26, against −₹12.49 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to −₹6.19.

What is the Krebs Biochemicals and Industries ROE and ROCE?

Krebs Biochemicals and Industries' return on equity is not meaningful for FY26: shareholders' equity was negative (−₹163 crore on 31 March 2026), and a return on a negative base has no sign that can be read. Its return on capital employed (ROCE) was −20.5% — operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the Krebs Biochemicals and Industries shareholding pattern?

On 30 September 2026, Krebs Biochemicals and Industries' shares were held by promoters 72.74%, foreign portfolio investors (FII/FPI) 0.50% and retail and other non-institutional investors 26.76%. Over the year, FII holding was unchanged.

Krebs Biochemicals and Industries vs Alpa Laboratories: how do they compare?

In FY26, Krebs Biochemicals and Industries earned net profit of ₹16.9 crore on revenue of ₹23.7 crore, against ₹15 crore on ₹106 crore for Alpa Laboratories. Krebs Biochemicals and Industries' operating margin was −50.0% (Alpa Laboratories 1.1%). At the 29 October 2026 close, Krebs Biochemicals and Industries' market capitalisation was ₹125 crore against ₹111 crore for Alpa Laboratories.

What is the Krebs Biochemicals and Industries promoter holding?

Promoters held 72.74% of Krebs Biochemicals and Industries on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Krebs Biochemicals and Industries free cash flow?

In FY26, Krebs Biochemicals and Industries generated ₹1.9 crore of cash from operations and spent ₹4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹5.9 crore. In FY25 it was −₹13 crore.

What is the Krebs Biochemicals and Industries revenue and profit in FY26?

In FY26 (April 2025–March 2026), Krebs Biochemicals and Industries' consolidated net loss was ₹16.9 crore, narrower than the loss of ₹26.9 crore in FY25, on revenue from operations of ₹23.7 crore (down 45.2%).

What are the Krebs Biochemicals and Industries latest quarterly results?

Krebs Biochemicals and Industries' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net loss ₹5.4 crore, narrower than the loss of ₹6.1 crore in Q2 FY26; revenue from operations ₹5.8 crore, up 38.9% year on year.

When are the Krebs Biochemicals and Industries next results?

Krebs Biochemicals and Industries has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does Krebs Biochemicals and Industries compare with its peers?

On FY26 consolidated figures, against Alpa Laboratories, Bal Pharma and Vineet Laboratories: Krebs Biochemicals and Industries' operating margin of −50.0% is the lowest of the four (Alpa Laboratories 1.1%, Bal Pharma 6.7%, Vineet Laboratories 10.2%; peer average 6.0%); its revenue growth over three years of −23.1% a year is the third highest of the four (Alpa Laboratories 4.6% a year, Bal Pharma 0.8% a year, Vineet Laboratories −34.6% a year; peer average −9.7% a year).

Where do these Krebs Biochemicals and Industries figures come from?

From Krebs Biochemicals and Industries' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.